摘要
目的：探讨雌二醇治疗妇女围绝经期综合征的疗效，并对其进行安全性评估。方法选择2010年1月～2011年1月温州市龙湾区第一人民医院妇科收治的64例围绝经期综合征患者作为观察组，该组患者使用戊酸雌二醇治疗；择同期收治的64例围绝经期综合征患者为对照组，该组患者接受常规治疗。治疗结束后,采用汉密尔顿抑郁量表（Hamilton Depression Scale，HAMD）评分和Kupperman评分标准对2组的症状改善效果进行评价，并检测2组治疗前后相关激素水平，观察治疗后不良反应发生情况。结果临床结果显示2组患者治疗后的HAMD评分和Kupperman评分均要显著好于治疗前（P＜0.05），且观察组的改善程度显著好于对照组（P＜0.05）；治疗后观察组的各项激素指标改善效果显著好于对照组（P＜0.05）；观察组治疗后出现8例不良反应，对照组出现12例不良反应，表现为乳房胀痛、阴道出血和胃肠道不适等，2组差异比较不显著。结论雌二醇治疗围绝经期妇女综合症的效果明显，改善了绝经期症状，不良反应少，提高了围绝经期妇女的生活质量。
Objective To investigate the clinical efifcacy of estradiol on perimenopausal syndrome,and evaluate its safety. Methods 64 cases with perimenopausal syndrome collected in our hospital from January 2010 to January 2011 were used as observation group, and treated with Estradiol valerate. Another 64 cases during the same period were used as control group, and treated with conventional therapy. After treatment, the symptom improvement of both groups were evaluated by the scoring criteria of HAMD and Kupperman, and the related hormone levels were detected and recorded. Adverse reactions after treatment were also observed. Results Clinical results showed that the HAMD and Kupperman score of both groups in end of treatment were better than before treatment, and the improvement degree in observation group were better than control in. The differences were signiifcant (P<0.05). Test results showed that the improvement of various hormonal indicators in observation group were also better than that in control group, the diffierences were significant (P<0.05). 8 cases of adverse reactions were observed in observation group after treatment, 12 cases in control group. Adverse reactions included breast tenderness, vaginal bleeding and gastrointestinal discomfort. The side effects between both groups had no signiifcant difference. Conclusion The efifcacy of Estradiol on perimenopausal syndrome was obvious, it can improve the menopausal symptoms, with less adverse reactions, and improve the life quality of perimenopausal women.
出处
《中国生化药物杂志》
CAS
北大核心
2014年第2期91-93,共3页
Chinese Journal of Biochemical Pharmaceutics
基金
浙江省医药卫生一般研究计划(2011KYB086)
